Azarest 300 Mg (Azacitidine) – 14 Tablets

Introduction Of Azarest 300 Mg

Azarest 300 mg is a highly effective chemotherapy drug used primarily in the treatment of blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Manufactured by Everest Pharmaceuticals in Bangladesh, Azarest contains the active ingredient Azacitidine, an FDA-approved hypomethylating agent. This medicine is available as oral tablets, specifically in the 300 mg dose, providing patients across the USA, Saudi Arabia, Australia, Kazakhstan and other countries a convenient and affordable treatment option.

 

What is Azacitidine?

Azacitidine is a DNA methyltransferase inhibitor and part of a class of epigenetic therapies designed to reverse abnormal DNA methylation patterns found in cancer cells. By reactivating tumor suppressor genes, Azacitidine helps inhibit the uncontrolled proliferation of malignant cells. It is an important antineoplastic agent used to treat several myeloid malignancies, including chronic myelomonocytic leukemia (CMML) and relapsed or refractory AML.

 

Azacitidine is available in both oral tablet and injectable forms. The Azarest 300 mg oral tablet offers patients an easier administration route compared to injections, improving compliance and quality of life during treatment.

 

How Does Azarest 300 Mg Work?

Azarest 300 mg targets cancerous cells in the bone marrow by affecting the hematopoietic stem cells responsible for blood cell production. Its mechanism of action includes:

• Inhibition of DNA methyltransferase (DNMT): This reduces DNA methylation in malignant cells, leading to gene reactivation.
• Epigenetic modulation: Reactivating silenced tumor suppressor genes to restore normal cellular function.
• Cytotoxicity: Selectively damaging cancerous cells while sparing healthy cells.
• Immunomodulatory effects: Enhancing the immune system’s ability to attack malignant cells.
• Pharmacodynamics and pharmacokinetics: Azacitidine demonstrates rapid absorption and effective bioavailability when administered orally.

This multifaceted action helps to restore normal hematopoiesis and decrease the progression of blood cancers.

 

Indications and Uses of Azarest 300 Mg

Azarest 300 mg is prescribed for the treatment of:

• Acute myeloid leukemia (AML): A fast-progressing cancer of the bone marrow and blood characterized by the rapid growth of abnormal white blood cells.
• Myelodysplastic syndromes (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells.
• Chronic myelomonocytic leukemia (CMML): A rare form of leukemia with features overlapping myelodysplastic and myeloproliferative diseases.

It is especially useful in patients with relapsed or refractory AML and is recommended by international guidelines, including those from the Mayo Clinic and National Comprehensive Cancer Network (NCCN).

 

Dosage and Administration

Azarest 300 mg tablets are taken orally, with dosage typically prescribed in cycles. Treatment details include:

Dosage Form	Strength	Administration Route	Typical Frequency
Azarest Tablets	300 mg	Oral	Daily for 7 days every 28 days

• The treatment cycle usually lasts 28 days, with the medication taken once daily for 7 consecutive days.
• Dose adjustments may be required based on patient tolerance and blood counts.
• Oral tablets improve convenience compared to injectable Azacitidine, reducing hospital visits.
• Patients should follow medical advice closely to maximize efficacy and minimize side effects.

 

Side Effects and Precautions

As with all chemotherapy agents, Azarest 300 mg may cause side effects. These range from mild to severe and require careful monitoring:

Common side effects:

• Nausea and vomiting
• Fatigue and weakness
• Low blood cell counts (neutropenia, anemia, thrombocytopenia)
• Increased risk of infections
• Fever and chills

Less common side effects:

• Hair thinning or loss (less common with oral tablets)
• Injection site reactions (mainly with injectable forms)
• Gastrointestinal discomfort

Important Precautions:

• Regular complete blood count (CBC) monitoring is essential to detect bone marrow suppression early.
• Discuss all current medications with your healthcare provider to avoid dangerous drug interactions.
• Azarest 300 mg is contraindicated in patients with hypersensitivity to Azacitidine.
• The drug falls under pregnancy category C; consult your doctor before use during pregnancy or breastfeeding.
• Elderly patients may require dose adjustments based on health status.

Managing side effects promptly with supportive care can help maintain patient quality of life throughout therapy.

 

Clinical Trials and Approval

Azacitidine’s clinical efficacy has been validated through numerous Phase I, II, and III clinical trials showing significant benefits in blood cancer treatment:

• Clinical studies report improved remission rates and prolonged overall survival in AML and MDS patients treated with Azacitidine versus traditional chemotherapy.
• Azarest 300 mg and other generic forms have received FDA approval, with EMA approval in Europe, ensuring quality and safety.
• These regulatory endorsements underline Azacitidine’s role as a frontline treatment in hematologic oncology.

The drug’s consistent inclusion in guidelines by organizations like NCCN and Mayo Clinic highlights its established clinical utility.

 

Pricing and Availability

Manufactured by Everest Pharmaceuticals in Bangladesh, Azarest 300 mg is competitively priced, making it accessible globally, especially in regions like, the USA, Saudi Arabia, Kazakhstan, Australia and beyond.

Pack Size	Approximate Price (USD)	Availability
7/14 – tablets/pack	$150 – $350	USA, Saudi Arabia, Australia via pharmacies and online

Buying Azarest through authorized channels ensures product authenticity and access to customer support. Prices may vary by country due to import fees and regulations.

Prices may vary based on location, pharmacy, and insurance coverage. Purchasing Azarest online from reliable sources ensures product authenticity and convenience.

 

Alternatives and Combination Therapy

Alternative treatments to Azacitidine include:

• Vidaza: Brand-name Azacitidine, often injectable.
• Decitabine: Another hypomethylating agent with similar indications.
• Lenalidomide: Used in certain MDS cases.
• Stem cell transplant: Curative option for eligible patients.
• Combination therapies incorporating Azacitidine with other chemotherapy drugs or targeted agents are under active research to improve patient outcomes.

Consult your hematologist to explore personalized treatment plans tailored to your condition.

 

Frequently Asked Questions (FAQs)

Q: What is Azarest 300 mg used for?
A:  It treats blood cancers including AML, MDS, and CMML by targeting abnormal blood cells.

Q: Is Azacitidine chemotherapy?
A: Yes, it is a chemotherapy drug classified as a hypomethylating agent.

Q: Does Azacitidine cause hair loss?
A: Hair loss is less common with oral Azacitidine tablets but can occur in some patients.

Q: How should I take Azarest 300 mg?
A: Take it orally once daily for 7 days in a 28-day cycle, following your doctor’s prescription.

Q: What side effects should I expect?

A: Common effects include nausea, fatigue, and low blood counts; your doctor will monitor these closely.

Q: Is Azarest 300 mg FDA approved?
A: Yes, Azacitidine, including generic oral forms like Azarest, is FDA-approved.

Q: How much does Azarest 300 mg cost?
A: Pricing varies, but it is generally affordable due to local manufacturing, ranging from $150 to $350 per pack.

 

Patient Support and Monitoring

Patients taking Azarest should:

• Undergo regular blood count and organ function tests.
• Report side effects immediately to healthcare providers.
• Participate in patient support programs to aid compliance and manage treatment effects.
• Understand the importance of adhering to prescribed dosage schedules for maximum effectiveness.

Healthcare providers emphasize education and monitoring to optimize patient outcomes.

 

Conclusion

Azarest 300 mg, containing the active ingredient Azacitidine, is a frontline oral chemotherapy agent manufactured by Everest Pharmaceuticals. Its proven efficacy in treating AML, MDS, and CMML, combined with FDA and EMA approval, make it a trusted choice worldwide. With proper medical supervision and adherence to treatment protocols, Azarest 300 mg offers hope for patients battling blood cancers in the USA, Saudi Arabia, Australia, Kazakhstan and beyond.

Always consult your healthcare provider for personalized advice and treatment plans.